Aeovian Pharmaceuticals Raises $37 Million Series A Financing to Advance Selective mTORC1 Inhibitors into the Clinic for Rare and Age-Related Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2LL6sdt
via IFTTT